ABSTRACT
Objective:To investigate the mechanism of 640 nm red light promoting keratinocyte migration preliminarily. Methods:Human keratinocytes were cultured in vitro and assigned to 4 groups according to different interventions, i.e. control group, sitagliptin group (CD26 expression inhibited), 640 nm red light group (8 J/cm2) and 640 nm red light+sitagliptin group. The levels of CD26 mRNA and protein in keratinocytes were measured with realtime-PCR and Western blotting, respectively. Cell migration was observed with Transwell assay and scratch assay. Results:The level of CD26 mRNA and the expression of CD26 protein in 640 nm red light group obviously increased compared with control group, while those of sitagliptin group significantly decreased. Migration ability of keratinocytes increased in 640 nm red light group and decreased in sitagliptin group observed by Transwell assay and scratch assay. Conclusion:The expression of CD26 in keratinocytes is promoted by the 640 nm red light, which can accelerate keratinocyte migration to facilitate re-epithelialization.
ABSTRACT
In recent years, researchers have found that CD26 (dipeptidyl peptidase 4) is closely related to the formation and development of many fibrotic diseases. Hypertrophic scar, keloid, and other skin fibrosis diseases are major problems nowadays, which may affect the patient′s appearance and cause joints deformity and dysfunction due to scar contracture. This article briefly reviews the relationship between CD26 and hypertrophic scar and keloid to provide new insights into the treatment of skin fibrotic diseases.
ABSTRACT
BACKGROUND/AIMS: Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression by activating Toll-like receptor 4. The aim of this study was to correlate the serum levels of LPS and CD26 in Crohn's disease (CD) patients with serum levels of C-reactive protein (CRP), interleukins, CD activity index, and tumor necrosis factor-α (TNF-α). METHODS: Serum samples were collected from 27 individuals (10 with active CD, 10 with inactive CD, and 7 controls) and the levels of LPS, CD26, TNF-α, interleukin-1β (IL-1β), IL-6, IL-17, and CRP were determined by enzyme-linked immunosorbent assay. The levels of LPS and CD26 were then tested for correlation with TNF-α, IL-1β, IL-6, IL-17, and CRP. RESULTS: Serum levels of LPS were significantly elevated in the active CD group (P=0.003). Levels of IL-1β (P=0.002), IL-6 (P=0.003), and IL-17 (P<0.001) were lower in the CD groups. Serum TNF-α levels were increased in the active CD group. The CRP levels were elevated in the CD groups when compared to controls (P<0.001). The CD26 levels were lower in the CD groups than in the control group (P<0.001). Among the variables analyzed, there was a correlation between LPS and CRP (r=−0.53, P=0.016) in the CD groups. CONCLUSIONS: Individuals with CD exhibited higher serum levels of LPS varying from a 2- to 6-fold increase depending on disease activity, when compared with healthy controls. CD26 levels were lower in the CD groups. Both LPS and CD26 correlated with disease severity and serve as potential CD biomarkers.
Subject(s)
Humans , Biomarkers , C-Reactive Protein , Cell Wall , Crohn Disease , Enzyme-Linked Immunosorbent Assay , Gram-Negative Bacteria , Inflammatory Bowel Diseases , Interleukin-17 , Interleukin-6 , Interleukins , Lipopolysaccharides , Necrosis , Polysaccharides , Toll-Like Receptor 4ABSTRACT
Objective:To explore the diagnostic value of CD26 expression in endometrial carcinoma (EC) by testing CD26 expression in normal proliferative phase, in secretory phase, and in the tissues of different pathological grades of EC;and by investigating the solu-ble CD26 (sCD26) expression in the serum of non-EC patients and EC patients. Methods:Endometrial tissue specimens were collected from patients who received diagnostic curettage or surgical treatment for other reasons in the Affiliated Hospital of Nantong Universi-ty from January 2014 to December 2015. The above endometrial specimens, included 30 specimens of normal proliferative phase, 30 specimens of secretory phase, and 120 type I EC tissue samples of G1, G2, and G3 grades. The expression of CD26 among these speci-mens were detected by immunohistochemistry. After the expression level of the CD26 protein was verified at the tissue, we continued to collect blood specimens from the outpatients. These patients received physical examination, and included healthy women of child-bearing age and type I EC patients. The patients received treatment in our hospital from January 2016 to September 2017. Of the blood samples collected, 20 cases were in proliferative phase and 20 cases were in secretory phase. Samples were also collected from patients with different grades of EC, including 20 cases of type I EC G1 grades, 20 cases of G2 grades, and 15 cases of G3 grades. The expression level of sCD26 in serum was detected by enzyme-linked immunosorbent assay (ELISA). Results:According to the results of immunohistochemistry, the order of the CD26 expression levels in normal endometrial tissues were as follows:secretory phase>prolif-erative phase, with a statistically significant difference observed among these groups (P<0.05). The order of the CD26 expression level among different type 1 EC grades were as follows: G3>G2>G1, with statistically significant differences also observed among these groups (P<0.05). The results of ELISA suggested that the expression level of CD26 in serum was associated with tumor progression, with statistically significant differences observed among the groups (P<0.05). Conclusion:The expression of CD26 in EC tissue and se-rum is associated with disease progression. The expression of CD26 in serum could be used as a marker for the diagnosis of EC.
ABSTRACT
Objective To investigate the expression of CD26 (dipeptidyl peptidase 4) in the kidney tissues of diabetic rats and the effects of mycophenolate mofetil (MMF) on the renal CD26 expression.Methods Wistar rats were randomly divided into three groups:normal control group (NC group,n=7),diabetic model group (DM group,n=7) and MMF-treated group (MMF group,n=7).Wistar rats were fed with high-sucrose-high-fat diet and injected with streptozotocin into abdominal cavity to induce diabetes.Sixteen weeks later,blood glucose (BG),blood urea nitrogen (BUN),serum creatinine (Scr),renal hypertrophy index (kidney weight]body weight) and 24 hour urinary protein (24Upro) were measured.The number of CD37CD4+ T cells in renal tissues were measured through flow cytometry.The expression of CD26 in kidney was examined by using Western blotting and immunohistochemistry.Results Compared with NC group,BG,BUN,Scr,kidney weight/body weight,24Upro were significantly increased in DM group (P ＜ 0.05).Except BG and kidney weight] body weight,the above-mentioned parameters were lower in MMF group compared with that in DM group (P ＜ 0.05).Intrarenal CD37CD4+ T cells were significantly up-regulated in DM group compared with that in NC group (P ＜ 0.01).CD26 in renal tissue was mainly expressed in T lymphocytes of renal interstitium.CD26 expression in DM group was significantly higher than that in NC group,and also higher than that in MMF group (P ＜ 0.05).In DM group,CD26+ T lymphocytes infiltration of renal interstitium was positively correlated with 24Upro (r2=0.770,P ＜ 0.05).Conclusions CD26 is related with diabetic nephropathy.MMF maybe inhibit T lymphocytes infiltration to reduce the expression of CD26 in renal interstitium,thus protecting the kidney function.
ABSTRACT
Objective To investigate the expression of bradykinin as a substrate of CD26/DPP Ⅳ in rats with ischemia/reperfusion injury following lung transplantation (LTx). Methods Thirty-six syngeneic male SD rats were randomly allocated into control group and experimental group (n= 18each), and 36 rats served as donors. In control group and experimental group, the lungs were flushperfused and preserved with LPD and LPD+ CD26/DPP TV catalytic inhibitor (AB192) respectively,and LTx was performed 18 h after cold ischemia Histopathological studies were also done on the same locus of lung specimens and staining for bradykinin. The different proteins were separated by means of immobilized PH gradient-based two-dimensional gel electrophoresis. The differential expression of bradykinin was compared by Western blotting. Results The expression of bradykinin in control group was significantly higher than in experimental group. As compared with experimental group,bradykinin expression was significantly up-regulated in control group (P <0 . 05 ). Conclusion Inhibitor of CD26/DDP Ⅳ enzymatic activity significantly ameliorated ischemia/reperfusion injury in the early stage after LTx, which is probably associated with inhibition of the protein expression of bradykinin.
ABSTRACT
Objective To observe the expressions of CD26, Ki67 and epidermal growth factor receptor(EGFR) proteins in thyroid neoplasms, to explore their value in differential diagnosis between benign and malignant thyroid neoplasms and to search for molecular marker in well-differentiated thyroid carcinomas.Methods The expressions of CD26,Ki67and EGFR proteins were examined by immunohistochemistry in 50 differentiated thyroid carcinomas (TC) and 50 thyroid adenomas (TA) and their relationships were analyzed.Results The positive rate and expression intensity of CD26,Ki67and EGFR proteins in TC were significantly higher than those in TA, and especially higher in follicular TC than those in follicular TA.Conclusion The abnormal expressions of CD26, Ki67and EGFR proteins appear to be valuable in differential diagnosis and predicting prognosis of thyroid carcinomas, especially CD26 can be used as a diagnostic marker in well-differentiated carcinoma of follicular cell origin.
ABSTRACT
Objective To explore the expression and significance of CD26/DPPⅣand galectin-3 in papillary thyroid carcinoma.Methods Expression of CD26/DPPⅣ or galectin-3 in 68 papillary thyroid carcinomas and 36 thyroid adenomas were determined with EnVision immunohistochemical technique respectively.Results CD26/DPPⅣ and galectin-3 were highly expressed in most of papillary carcinomas but absent or expressed in a low level in most of all thyroid adenomas.With CD26/DPPⅣ as marker to detect papillary carcinoma,the sensitivity,specificity,diagnostic accuracy were 86.8%,97.2% and 90.4%,and with galectin-3 the respective figures were 97.1%,91.7% and 95.2%.There was no statistic significance in intrathyroidal and extrathyroidal invasion,with or without lymph node metastasis,low and poor prognosis groups about positive expression of CD26/DPPⅣ or galectin-3 in papillary carcinomas.Conclusion Both CD26/DPPⅣ and galectin-3 are potential markers of papillary thyroid carcinoma.CD26/DPPⅣ or galectin-3 immunohistochemical staining can be used as a supplement technology for routine pathological diagnosis to differentiate thyroid papillary carcinomas from adenomas,but not accepted as the bio-markers for the invasion,metastasis and prognosis of papillary thyroid carcinomas.
ABSTRACT
Objective To establish a PCR-RFLP method for detection of CD26 mutation of hemoglobin E(HbE)gene.Methods The genome DNA from the family members who were suspected of having HbE combined with beta-thalassemia was amplified using PCR.The PCR products were digested by restriction endonuclease Mnl I,and then separated on PAGE.The electrophoretical patterns were finally analyzed to confirm if CD26 mutation was present or not.Results Four cases with CD26 mutation in two families were successfully screened out.Conclusion Although the incident frequency of CD26 mutation in Sichuan population is not high,it must not be neglected since it may present alone or combined with other type of thalassemia.PCR-RFLP method described in this study is available in screening mutated HbE gene and treating the disease owing to its simplicity,rapidity and specificity.
ABSTRACT
BACKGROUND: Cytokine response changes with ageing. CD26 is known as an operational marker for Th1 pathway. In this study we investigated the possibility of CD26 as a practical marker for immunosenescence, Th1 or Th2 polarization. METHODS: We studied 99 subjects from 4 groups divided by age (thirties and sixties) and by hepatitis B. CD26 expression in T cells in peripheral blood was investigated by 3 color flow cytometry. Especially, CD26 expression in activated (HLA-DR+) T cells was compared among each group. RESULTS: CD26 expression in total T cells had the trend toward a decrease with ageing and decreased significantly especially in Ts cells (from 45.9+/-11.3% to 37.5+/-12.4%, P<0.05). Regardless of hepatitis B, CD26 expression in activated Th cells was not significantly different between the two age groups. HLA-DR expression in total T cells had the trend toward an increase in the elderly or hepatitis B and the dominant T cell subset responsible for this increase was Ts cell subset in the elderly and was Th cell subset in hepatitis B. CONCLUSIONS: We could not find the possibility of CD26 as a practical marker for immunosenescence reflecting Th1 polarization in activated Th cells. But CD26 or HLA-DR expression in total T cells had the trend to change with ageing and the change in Ts cells was more dominant than in Th cells.
Subject(s)
Aged , Humans , Flow Cytometry , Hepatitis B , HLA-DR Antigens , T-LymphocytesABSTRACT
ObjectiveTo investigate the value of CD26/DPPⅣ or galectin-3 immunohistochemical staining and their combination in the diagnosis of thyroid carcinoma. MethodsEnVision immunohistochemical technique was applied to detect the expressions of CD26/DPPⅣ and galectin-3 in thyroid tissue of 114 cases with benign or malignant thyroid tumors. ResultsCD26/DPPⅣ and galectin-3 were expressed in most of papillary carcinomas but absent in normal thyroid tissues, most of follicular carcinomas and thyroid adenomas. With CD26/DPPⅣ as means to detect papillary carcinoma, the sensitivity, specificity, diagnostic accuracy, positive predictive value, negative predictive value and Kappa index were 86.8%, 97.2%, 90.4%, 98.3%, 79.5% and 0.80 respectively,andwithgalectin-3therespective figures were 97.1%, 91.7%, 95.2%, 95.7% , 94.3% and 0.89. With CD26/DPPⅣ and gelectin-3 combined, the sensitivity, specificity, Kappa index and others in papillary carcinoma were the same as those of galectin-3 in parallel test, and the same as those of CD26/DPPⅣ in serial test. ConclusionBoth CD26/DPPⅣ and galectin-3 are reliable markers of papillary carcinoma, CD26/DPPⅣ or galectin-3 immunohistochemical staining can be used as a supplement for conventional pathological diagnostic approach to differentiate thyroid papillary carcinomas from adenomas, while the application in the diagnosis of follicular thyroid carcinoma remains to be further investigated.